Status: Recruiting
Treatment of Relapsed or Refractory Epstein-Barr Virus Positive T-cell Lymphoma With hNeo-T
Objective: To evaluate the safety and tolerability of hNeo-T injection in patients with relapsed or refractory EBV-positive T-cell lymphoma. Secondary objective: To evaluate the effectiveness of hNeo-T injection, and to evaluate the objective response rate (ORR) and disease control rate (DCR) by Lugano2014 criteria; Progression-free survival (PFS), duration of response (DOR), and overall survival (OS ) followed. Objective of the exploratory study: To investigate the in vivo process of hNeo-T injection and describe the activity and related biological functions of hNeo-T cells in vivo, including but not limited to.
Participants needed: 6
Trial details
Phase: Early Phase 1Age: 18-75Biological sex: AllType: InterventionalSponsor: BGI, ChinaUpdated: Mar 12, 2024Locations: 1
Eligibility criteria
Age ≥18 years old, and ≤75 years old, gender is not limited; [+12]
Pregnant or lactating women; [+13]